M
Matteo Simonelli
Researcher at Humanitas University
Publications - 113
Citations - 2531
Matteo Simonelli is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Pemetrexed. The author has an hindex of 23, co-authored 93 publications receiving 1897 citations.
Papers
More filters
Journal ArticleDOI
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Patrick A. Ott,Sarina Anne Piha-Paul,Pamela N. Munster,Michael J. Pishvaian,E. van Brummelen,Roger B. Cohen,Carlos Gomez-Roca,Samuel Ejadi,Mark N. Stein,Emily Chan,Matteo Simonelli,Anne Morosky,Sanatan Saraf,Kenneth Emancipator,Minori Koshiji,Jaafar Bennouna +15 more
TL;DR: In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity.
Journal ArticleDOI
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Giovanni Luca Ceresoli,Paolo Andrea Zucali,Fabio De Vincenzo,Letizia Gianoncelli,Matteo Simonelli,Elena Lorenzi,C. Ripa,Laura Giordano,Armando Santoro +8 more
TL;DR: Re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC.
Journal ArticleDOI
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Paolo Andrea Zucali,Tommaso De Pas,Giovannella Palmieri,Adolfo Favaretto,Antonio Chella,Marcello Tiseo,Michele Caruso,Matteo Simonelli,Matteo Perrino,Fabio De Vincenzo,Francesca Toffalorio,Vincenzo Damiano,Giulia Pasello,Erika Garbella,M. Ali,Fabio Conforti,Margaret Ottaviano,Angela Cioffi,Sabino De Placido,Laura Giordano,Monica Bertossi,Annarita Destro,Luca Di Tommaso,Armando Santoro +23 more
TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.
Journal ArticleDOI
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Vanesa Gregorc,Paolo Andrea Zucali,Armando Santoro,Giovanni Luca Ceresoli,Giovanni Citterio,Tommaso De Pas,Nicoletta Zilembo,Fabio De Vincenzo,Matteo Simonelli,Gilda Rossoni,Anna Spreafico,Maria Grazia Viganò,Floriana Fontana,Filippo de Braud,Emilio Bajetta,Federico Caligaris-Cappio,Paolo Bruzzi,Antonio Lambiase,Claudio Bordignon +18 more
TL;DR: The tolerability and disease control of NGR-hTNF 0.8 microg/m(2) weekly warrant additional evaluation in patients with advanced MPM.
Journal ArticleDOI
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience
Federico Pessina,Pierina Navarria,Luca Cozzi,Anna Maria Ascolese,Matteo Simonelli,Armando Santoro,Elena Clerici,Marco Rossi,Marta Scorsetti,Lorenzo Bello +9 more
TL;DR: Surgical resection beyond contrast-enhancing boundaries could represent a promising strategy to improve outcome in GBM patients and it was recorded as factor influencing survival.